Profile data is unavailable for this security.
About the company
Dottikon ES Holding AG is a Switzerland-based holding company that specializes in hazardous chemistry and focuses on the exclusive synthesis of fine chemicals for the pharmaceutical and chemical industries. Its product range includes active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, as well as industrial chemicals. Its pharmaceutical products can be found in medications for, among others, heart disease, asthma, high blood pressure and ulcers. Dottikon ES Holding AG's industrial end products include food additives, cosmetics, electro-chemicals, photo-chemicals and agricultural chemicals. The Company also offers distillation plants and thin layer evaporators for the recycling of solvents, as well as high temperature incinerators for the waste treatment of hazardous waste. As of March 31, 2012, the Company had two wholly owned subsidiaries: DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG. It also held a 33.9%-stake in SYSTAG, System Technik AG.
- Revenue in CHF (TTM)326.27m
- Net income in CHF80.63m
- Incorporated2005
- Employees726.00
- LocationDottikon Es Holding AG5605PO. BoxDOTTIKON 5605SwitzerlandCHE
- Phone+41 566168201
- Fax+41 566168945
- Websitehttps://dottikon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bluestar Adisseo Co | 1.71bn | 75.75m | 3.27bn | 2.73k | 43.12 | 1.78 | -- | 1.91 | 0.2336 | 0.2336 | 5.26 | 5.65 | 0.6549 | 5.03 | 7.54 | 5,163,249.00 | 2.91 | 5.28 | 3.52 | 6.94 | 26.31 | 30.31 | 4.44 | 8.76 | 1.08 | 6.12 | 0.0989 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 979.43m | 111.49m | 3.41bn | 4.62k | 24.22 | 3.55 | -- | 3.48 | 1.19 | 1.19 | 10.50 | 8.14 | 0.7275 | 2.78 | 3.17 | 1,753,354.00 | 8.13 | 8.96 | 13.61 | 12.80 | 44.45 | 40.82 | 11.18 | 10.67 | 1.26 | -- | 0.1897 | 56.93 | -0.3266 | 5.28 | 14.49 | 11.93 | -4.33 | 42.22 |
| Laboratorios Farmaceuticos ROVI SA | 736.62m | 140.16m | 3.49bn | 2.14k | 25.49 | 7.83 | 21.39 | 4.74 | 2.82 | 2.82 | 14.89 | 9.19 | 0.8855 | 0.8691 | 5.92 | 368,545.70 | 16.84 | 18.90 | 25.66 | 25.58 | 60.52 | 59.82 | 19.02 | 20.13 | 0.6801 | 313.46 | 0.2006 | 34.37 | 1.44 | 22.30 | -14.69 | 56.93 | 15.84 | 69.11 |
| China Resources Pharmaceutical Group Ltd | 30.30bn | 456.54m | 3.53bn | 72.76k | 7.74 | 0.6043 | 2.53 | 0.1167 | 0.6652 | 0.6652 | 44.15 | 8.52 | 0.966 | 6.09 | 3.00 | 3,800,307.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Dottikon ES Holding AG | 326.27m | 80.63m | 3.56bn | 726.00 | 43.52 | 3.95 | 35.11 | 10.90 | 5.84 | 5.84 | 23.62 | 64.31 | 0.2905 | 0.6518 | 5.23 | 449,407.70 | 7.18 | 7.83 | 8.39 | 8.95 | 66.55 | 75.24 | 24.71 | 24.25 | 1.57 | -- | 0.1014 | -- | 2.13 | 17.17 | -8.08 | 37.75 | 26.82 | -- |
| Humanwell Healthcare Group Co Ltd | 3.02bn | 232.41m | 3.56bn | 17.68k | 15.19 | 1.70 | -- | 1.18 | 1.19 | 1.19 | 15.46 | 10.60 | 0.6804 | 3.75 | 2.76 | 1,414,518.00 | 7.02 | 6.20 | 13.11 | 12.72 | 45.61 | 42.82 | 10.32 | 9.84 | 1.21 | 13.69 | 0.3347 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
| Axsome Therapeutics Inc | 247.90m | -262.41m | 3.67bn | 545.00 | -- | 41.79 | -- | 14.81 | -6.51 | -6.51 | 6.15 | 2.15 | 0.5026 | 2.31 | 3.11 | 534,842.20 | -53.20 | -64.55 | -71.90 | -82.23 | 90.30 | -- | -105.85 | -227.05 | 2.40 | -79.61 | 0.6409 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Corcept Therapeutics Incorporated | 484.42m | 107.14m | 3.78bn | 352.00 | 37.41 | 7.45 | 35.02 | 7.80 | 1.14 | 1.14 | 5.14 | 5.71 | 0.9193 | 1.12 | 13.19 | 1,618,210.00 | 20.33 | 21.17 | 24.10 | 23.85 | 98.49 | 98.52 | 22.12 | 27.23 | 5.48 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Santen Pharmaceutical Co Ltd | 1.79bn | 157.75m | 3.83bn | 3.74k | 23.98 | 2.08 | 14.27 | 2.14 | 74.76 | 74.76 | 844.65 | 862.32 | 0.7155 | 2.68 | 3.25 | 81,289,260.00 | 6.32 | 3.31 | 7.84 | 4.10 | 58.85 | 59.73 | 8.84 | 5.21 | 2.03 | 5.27 | 0.1604 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| ADMA Biologics Inc | 280.86m | 29.59m | 3.86bn | 624.00 | 138.61 | 24.12 | 105.28 | 13.76 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| IPCA Laboratories Ltd | 835.34m | 58.67m | 3.87bn | 17.34k | 65.90 | -- | 40.07 | 4.63 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
Data as of Sep 26 2024. Currency figures normalised to Dottikon Es Holding AG's reporting currency: Swiss Franc CHF
7.85%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 31 Mar 2024 | 585.42k | 4.18% |
| VV Verm�gensverwaltung AGas of 28 Jun 2024 | 219.60k | 1.57% |
| Z�rcher Kantonalbank (Investment Management)as of 31 Jul 2024 | 113.98k | 0.81% |
| Union Bancaire Priv�e, UBP SAas of 31 Mar 2024 | 68.74k | 0.49% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 30.08k | 0.22% |
| Reichmuth & Co.as of 30 Jun 2024 | 25.00k | 0.18% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 16.38k | 0.12% |
| Pax Asset Management AGas of 31 May 2024 | 16.00k | 0.11% |
| Deka Investment GmbHas of 30 Jun 2024 | 13.55k | 0.10% |
| FIVV Finanzinformation & Verm�gensverwaltung AGas of 29 Feb 2024 | 10.67k | 0.08% |
More ▼
Data from 28 Jun 2024 - 31 Jul 2024Source: FactSet Research Systems Inc.
